) Since its origin in Fall 1996, the Pharmacology Core has steadily grown into being an important CCC resource for several investigators. Its mission is providing expertise in pharmacological sciences, including kinetics, dynamics, biopharmaceutics and physical pharmacy. Pharmacokinetic support includes drug absorption, metabolism, distribution, elimination, bioactivation and drug-drug interactions. Pharmacodynamic support includes molecular effects of drug exposure, and in vitro toxicity testing. Biopharmaceutic support includes the influence of dose and dosage form on pharmacokinetics. Physical pharmacy support includes production of (approximate dose) prototype forms of drugs for preclinical studies and clinical forms for IND studies. Enhancements of research by the Core take the form of study design, data acquisition, data analysis, and interpretation of results, including technical writing for manuscripts and grant proposals written by CCC investigators. This core also developed and oversees the Quality Assurance Plan for tracking and handling clinical pharmacology specimens throughout the Institute. Key features of this Core are the scope of services provided, its integral role in clinical specimen handling, existing collegial relationships, direct consultation for requesting investigators, and the interests and commitment of its staff. Pharmacological contributions benefited 5 Programs, including Developmental Therapeutics, Breast Cancer, Molecular Biology and Genetics, Prostate Cancer and Protease Programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA022453-22S1
Application #
6503921
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-09-27
Project End
2001-11-30
Budget Start
Budget End
Support Year
22
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008
Cheriyan, Vino T; Alsaab, Hashem; Sekhar, Sreeja et al. (2018) A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers. Oncotarget 9:29680-29697
Saadat, Nadia; Liu, Fangchao; Haynes, Brittany et al. (2018) Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy. Mol Cancer Ther 17:2586-2597
Dedigama-Arachchige, Pavithra M; Acharige, Nuwan P N; Pflum, Mary Kay H (2018) Identification of PP1-Gadd34 substrates involved in the unfolded protein response using K-BIPS, a method for phosphatase substrate identification. Mol Omics 14:121-133
Burl, Rayanne B; Ramseyer, Vanesa D; Rondini, Elizabeth A et al. (2018) Deconstructing Adipogenesis Induced by ?3-Adrenergic Receptor Activation with Single-Cell Expression Profiling. Cell Metab 28:300-309.e4

Showing the most recent 10 out of 826 publications